SCYNEXIS INC (SCYX)
Nasdaq · Pharmaceutical Preparations
What they're doing
Between 2026-08-02 and 2026-10-31, public records show 4 signals for SCYNEXIS INC. Most notable: 2026-09-10: Filed 8-K disclosing director or officer change; 2026-09-22: Filed 8-K disclosing director or officer change; 2026-09-28: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $18,454,788. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-10-31 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Federal contract awardWon $18.5M federal contract action from Department of Health and Human Services
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement, acquisition or disposition of assets
- Material 8-K filingFiled 8-K disclosing material agreement
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-18 | Burke Steven Keith | director | A | 5,750 | 0 | $0 |
| 2026-06-26 | Tinmouth Brian Philippe | director | A | 2,875 | 0 | $0 |
| 2026-06-26 | Macdonald Guy | director | A | 2,875 | 0 | $0 |
| 2026-06-26 | ANIDO ARMANDO | director | A | 2,875 | 0 | $0 |
| 2026-06-26 | HASTINGS DAVID C | director | A | 2,875 | 0 | $0 |
| 2026-06-26 | HANHAM ANN | director | A | 2,875 | 0 | $0 |
| 2026-04-01 | Angulo Gonzalez David | director | P | 108,695 | — | — |
| 2026-01-29 | Macleod ivor | officer | A | 129,833 | 0 | $0 |
| 2026-01-29 | Sukenick Scott | officer | A | 129,833 | 0 | $0 |
| 2026-01-29 | Angulo Gonzalez David | director | A | 391,333 | 0 | $0 |
| 2025-10-17 | Angulo Gonzalez David | director | A | 32,500 | 0.76 | $24,700 |
| 2025-06-26 | Tinmouth Brian Philippe | director | A | 23,000 | 0 | $0 |
| 2025-06-26 | Macdonald Guy | director | A | 23,000 | 0 | $0 |
| 2025-06-26 | HASTINGS DAVID C | director | A | 23,000 | 0 | $0 |
| 2025-06-26 | HANHAM ANN | director | A | 23,000 | 0 | $0 |
| 2025-06-26 | GILMAN STEVEN C | director | A | 23,000 | 0 | $0 |
| 2025-06-26 | ANIDO ARMANDO | director | A | 23,000 | 0 | $0 |
| 2025-04-09 | Angulo Gonzalez David | director | A | 23,000 | 0.84 | $19,320 |
| 2025-03-20 | Angulo Gonzalez David | director | A | 13,800 | 1.05 | $14,490 |
| 2025-03-19 | Angulo Gonzalez David | director | A | 5,000 | 1.07 | $5,350 |
| 2025-01-23 | Sukenick Scott | officer | A | 92,511 | 0 | $0 |
| 2025-01-23 | Macleod ivor | officer | A | 92,511 | 0 | $0 |
| 2025-01-23 | Angulo Gonzalez David | director | A | 262,927 | 0 | $0 |
| 2024-09-12 | Angulo Gonzalez David | director | P | 20,000 | 1.37 | $27,400 |
Federal contracts
24-month federal obligations: $18,454,788
- 2026-09-25 $18,454,788 · Department of Health and Human Services · ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASI
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.